SciBase Holding AB has received an additional order worth approximately $0.6 million from Castle Biosciences to accelerate an ongoing clinical study and prepare for a second study. The collaboration focuses on using SciBase's AI-based Nevisense Go device to predict relapses in atopic dermatitis, a skin condition. Deliveries of the device and electrodes are expected to begin in Q4 2026. This expansion signals progress in their joint effort to improve therapies for patients with skin barrier dysfunctions.
General Electric (GE) announced it will acquire Consolidated Precision Products (CPP) for $11.75 billion to enhance its aerospace casting production. This strategic move aims to strengthen GE's manufacturing capabilities and accelerate engine technol...
Ionis Pharmaceuticals faced a setback when its experimental heart drug pelacarsen failed a Phase 3 trial to reduce cardiovascular events, causing an 8.6% stock drop. However, an analyst from Canaccord Genuity maintained a bullish $85 price target, im...
Casey's General Stores will release its Q3 2026 earnings on September 8 after market close, with analysts expecting an EPS of $6.78 and revenue of $5.56 billion. The company has a strong history of exceeding earnings estimates, with an average surpri...
Verisk Analytics introduced its new Verisk Fraud Discovery platform to enhance fraud prevention for insurers. Barclays adjusted the company's price target to $225, suggesting a 21.1% potential gain from the current stock price of $185.79. The company...
Adobe Inc. is undergoing a rare CEO transition with Anil Chakravarthy set to become CEO on December 1. Analyst opinions are divided: Oppenheimer rates Adobe as 'Perform' (hold), while Bank of America issues a 'Sell' rating with a $220 price target, c...
